Hepatology · Article 190

Who Still Needs Treatment for Hepatitis C?

Hepatitis C treatment requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Hepatitis C treatment clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

Hepatitis C treatment: practical clinical approach

This page focuses on Hepatitis C treatment with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Hepatitis C treatment

Clinical takeaway: For Hepatitis C treatment, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Nearly every patient with detectable HCV RNA should be offered curative direct-acting antiviral therapy unless life expectancy is too short to benefit and cannot be improved by HCV treatment, transplantation or another intervention. Modern pangenotypic regimens cure more than 95% of uncomplicated infections. Treatment is recommended in people who inject drugs, patients with chronic kidney disease and most patients with compensated cirrhosis. Decompensated cirrhosis, prior DAA failure and complex drug interactions require specialist-directed regimens.

Active infection means detectable RNA

A positive HCV antibody alone does not establish current infection.

Do not withhold treatment because of reinfection risk

People who inject drugs benefit from treatment and should also receive harm-reduction services.

Cirrhosis changes the regimen and follow-up

Decompensated cirrhosis requires specific specialist management and protease-inhibitor avoidance.

Practical clinical algorithm

1. Confirm HCV RNA.

2. Stage fibrosis/cirrhosis.

3. Review medications and HBV status.

4. Select a guideline-supported pangenotypic DAA regimen.

5. Confirm SVR at least 12 weeks after treatment.

6. Continue cirrhosis-specific surveillance after cure.

Common mistakes to avoid

Treating antibody positivity without confirming RNA.
Withholding therapy because the patient uses drugs.
Using protease inhibitors in decompensated cirrhosis.
Failing to check drug interactions.
Assuming cure removes HCC risk in cirrhosis.

Trainee takeaway

The modern default is simple: active hepatitis C should be cured.

Frequently asked questions

Do people with normal ALT need treatment?

Yes.

Should active drug use delay treatment?

No.

What defines cure?

Undetectable HCV RNA at least 12 weeks after treatment completion.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015.

2. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

3. AASLD-IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Current online guidance.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions